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hemodialyzer, and a constant hemodialyzer mass transfer
coefficient (KoA) over a wide range of hemodialysis
operating conditions.2 When QB and QD are low, however,
mismatch of these flows within the hemodialyzer creates a
shunt in which no solute transfer occurs. In a previous study
of nine patients during sustained low-efficiency dialysis, QB
of 200 ml/min and QD of 100 ml/min were used with a 1.8 m2
polysufone low-flux hemodialyzer.3 Measured Kd for urea by
direct dialysis quantification averaged 77.9 ml/min, as
opposed to B100 ml/min predicted by both Michael’s
equation and Dr Addis’ calculator. Hemodialyzer KoA during
sustained low-efficiency dialysis averaged only 203.2 ml/min,
much lower than the manufacturer’s value. Such errors in
calculated Kd are important as they lead directly to
misleading solute time–concentration profiles in Dr Conlon’s
dialysis simulation spreadsheet, which does not iteratively
recalculate solute generation rate and volume of distribution
to offset input error.4 Finally, critically ill patients with acute
kidney injury are seldom in solute steady state;5 this
assumption underpins Dr Conlon’s dialysis simulation
spreadsheet and is unrealistic. In summary, the calculators
by Walther et al.1 are useful for stable patients with end-stage
kidney disease, but are less suited for modelling acute renal
replacement therapy in the intensive care unit.
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We are grateful to Drs Marshall and Golper1 for pointing
out that when flows are low, dialyzers may not achieve the
clearance rates predicted from values for KoA that are
derived from clearances measured at higher flows. We
should have noted in addition that clearances in vivo are
often lower than those predicted from manufacturers’ KoA
values, which are usually derived from clearance experi-
ments performed with saline solutions. An even greater
problem is that KoA values are usually available only for
urea, creatinine, and vitamin B12, and must be guessed at
for other solutes of interest. We disagree somewhat with
Drs Marshall and Golper about the application of the
models to acute renal failure. We should emphasize that it
is only the downloadable format, and not the theoretical
content, of our models that is new. Like other theoretical
models, they can predict plasma solute concentrations only
when solute production rates, solute distribution volumes,
and residual renal function are specified, and these latter
parameters are both variable and hard to estimate in
acutely ill patients. But we think that the models can still
be useful in helping nephrologists to think about solutes
other than urea. An example may be provided by the
description of sustained low-efficiency dialysis with QB of
200 ml/min and QD of 100 ml/min to which Marshall and
Golper refer.2 If urea is the only solute considered, the
predicted clearance is not much different for QB of 200 ml/
min and QD of 100 ml/min as compared to QB of 100 ml/
min and QD of 200 ml/min. But the models predict that the
clearance of solutes, which bind to plasma proteins, will be
higher using QB of 100 ml/min and QD of 200 ml/min.
3 We
think it is wrong to assume that all uremic toxins behave
like urea, and that modeling the effect of renal replacement
therapies on other classes of solutes may thus have some
value.
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To the Editor: Consider a gene locus with two alleles, ‘A’ and
‘a’. The frequency of allele ‘A’ will be designated by p and that
of allele ‘a’ by q. Hardy and Weinberg showed that in a very
large population with random mating, the frequencies of AA,
Aa, and aa genotypes are p2, 2pq, and q2, respectively. The
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Hardy–Weinberg formulation also predicts that the allelic
frequencies will remain stable from generation to gene-
ration, provided that there is no mutation, no migration,
and no natural selection in a very large population with
random mating. If the evolutionary pressures are active and/
or when the mating is not random, we can observe a
significant deviation from the expected frequencies of the
genotypes.
I read the article of Lin et al.1 with great interest and I
would like to make a few comments about it. The authors
determined a genetic polymorphism in the promoter region
of heme oxygenase-1 gene and then investigated its associa-
tion with arteriovenous fistula failure in Chinese hemodia-
lysis patients in Taiwan. They also included 286 individuals
without renal disease as control group. A dinucleotide repeat
(GT) of different length was identified in the proximal
promoter region of the human heme oxygenase-1 gene. The
authors assigned those with GT repeats X30 as allele class L
(long) and those with GT repeatso30 as allele class S (short).
Based on Table 2 of the article of Lin et al.,1 61, 163, and 62
persons showed S/S, L/S, and L/L genotypes, respectively.
There is significant deviation from Hardy–Weinberg equili-
brium (w2¼ 5.595, df¼ 1, P¼ 0.025).
Unfortunately, the authors did not mention why their
control group is not on Hardy–Weinberg equilibrium. Is
there any problem for selecting the control subjects? The
observed frequency for the heterozygote genotype was 56.9%,
whereas the expected frequency of the genotype was 49.9%.
On the other hand, both homozygote genotypes were
decreased in the control group compared to expected values.
Therefore, it is possible that the control subjects were chosen
from at least two different gene pools (or different
populations). What we can say about the patients? If they
belong to different gene pools, is there any difference(s)
between these populations for the prevalence of coronary
artery disease, cardiovascular disease, and arteriovenous
fistula failure? Finally, it seems that the reliability of the
results of Lin et al.1 dramatically decreased, and therefore
their findings must be interpreted with caution.
1. Lin CC, Yang WC, Lin SJ et al. Length polymorphism in heme oxygenase-1
is associated with arteriovenous fistula patency in hemodialysis patients.
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The authors thank Saadat1 for raising an essential issue
regarding Hardy–Weinberg equilibrium in carrying out
case–control association studies. In our paper, the main
theme was to analyze the association between HO-1 repeat
polymorphisms and arteriovenous fistula patency in
patients underwent hemodialysis. Thus, the comparisons
were mostly based on differences of genotypes between the
two case groups, that is those with and without fistula
failure. Hardy–Weinberg equilibrium was not violated in
the two case groups; therefore, the tests that we performed
were valid and so did the conclusions.
We were aware of the deviation of Hardy–Weinberg
equilibrium for the control group; therefore, the test of
association between Huntington’s disease patients and
controls was carried out by Armitage’s trend test (a valid
test even in Hardy–Weinberg disequilibrium), which was
not mentioned in our paper. To clarify further, we now add
‘using Armigates’ trend test’ in the footnote of Table 2 after
‘* signifies the P-value for the comparison between
controls and Huntington’s disease patients’.
Regarding the variation among populations, we did
genotype three informative SNP markers for Chinese sub-
populations, rs727258, rs108996795, and rs10506294, to
rule out population stratification.2 The results supported
no difference between control and the two case groups
(data not shown).
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To the Editor: Robbin et al.1 have recently published an
interesting randomized study assessing the impact of
ultrasound surveillance on arteriovenous graft outcomes.
This study failed to prolong graft patency by means of
screening ultrasonography. This finding is in contradiction to
our randomized study,2 published a couple of months earlier,
where adding of ultrasound to clinical monitoring was
associated with significantly longer graft patency. A post hoc
analysis by Dossabhoy et al.3 supported our data.
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